Literature DB >> 7641202

Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.

J L Franco1, P Ghosh, R H Wiltrout, C R Carter, A H Zea, N Momozaki, A C Ochoa, D L Longo, T J Sayers, K L Komschlies.   

Abstract

Flavone-8-acetic acid plus recombinant human interleukin 2 is a successful antitumor therapy in mice bearing the Renca murine renal cell carcinoma. This report demonstrates that T cells, particularly CD8+ T cells, are critical for the generation of this response. Initial experiments examining T-cell signal transduction proteins demonstrated that T cells from Renca-bearing mice had undetectable levels of p56lck and zeta-chain of the T-cell receptor and that flavone-8-acetic acid and recombinant human interleukin 2 therapy could be used as a model for reversal of these alterations. However, further experimentation showed that the majority of the reduction in zeta-chain and part of the reduction in p56lck was due to degradation of these molecules during protein extraction caused by mature granulocytes contaminating the enriched T-cell population. This was not the case for nuclear c-Rel or NF kappa B p65, which remained at undetectable/reduced levels in the absence of granulocytes, confirming our previous data that transcription factor alterations exist in tumor-bearing mice. Thus, most of the reduction in zeta-chain in T cells from Renca-bearing mice is due to granulocyte contamination and emphasizes the need to use pure T-cell populations and/or sufficient amounts and types of protease inhibitors when quantitating proteins in T cells from tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641202

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 2.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

3.  NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.

Authors:  Cordelia Dunai; William J Murphy
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

4.  Myeloid suppressor cells regulate the adaptive immune response to cancer.

Authors:  Alan B Frey
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

5.  A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods.

Authors:  A M Deakin; K Singh; J S Crowe; J H Ellis; A Dalgleish; R J Leicester; C J Finlayson; W F Miles; P F Life
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

Review 6.  Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.

Authors:  Edwin J Vazquez-Cintron; Ngozi R Monu; Alan B Frey
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

7.  Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

Authors:  Srinivas Nagaraj; Adam G Schrum; Hyun-Il Cho; Esteban Celis; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2010-02-08       Impact factor: 5.422

Review 8.  Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship.

Authors:  Ngozi R Monu; Alan B Frey
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

Review 9.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 10.  Signaling defects in anti-tumor T cells.

Authors:  Alan B Frey; Ngozi Monu
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.